Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves - 01/09/11
Abstract |
Background: It has recently been suggested that regular treatment with racemic β2-adrenoceptor agonists might result in bronchial hyperresponsiveness (BHR) to a range of spasmogens, and this might be due to adverse effects of the distomer. Objective: We sought to determine whether BHR induced by means of continuous exposure to racemic and S-albuterol was mediated by sensory nerves. Methods: Naive or ovalbumin-sensitized guinea pigs were treated for 10 days with RS-, R-, or S-albuterol (1 mg·kg−1·d−1) through subcutaneously implanted minipumps. Lung function was then determined in response to a number of spasmogens and assessed on the basis of an increase in total airway resistance. A separate group of animals were chronically treated with capsaicin (80 mg/kg) before the albuterol treatment. Results: Treatment with RS- or S-albuterol increased airway responsiveness to bradykinin, leukotriene C4, and capsaicin in naive guinea pigs (P < .05) and to histamine and ovalbumin in immunized guinea pigs (P < .05). Chronic treatment with capsaicin prevented the development of RS- and S-albuterol-induced BHR in these models. The bronchodilator efficacy of acute intravenously administered RS-albuterol was unaffected in RS-, R-, or S-albuterol-treated guinea pigs compared with in vehicle-treated animals. Conclusion: We have provided evidence demonstrating that continuous exposure to RS- and S-albuterol increases bronchial responsiveness to a range of stimuli, an effect not attributed to β-adrenoceptor occupancy or desensitization. Furthermore, capsaicin-sensitive sensory nerves mediate the development of BHR, at least in part. (J Allergy Clin Immunol 2002;110:388-94.)
Le texte complet de cet article est disponible en PDF.Keywords : Albuterol, enantiomers, bronchial hyperresponsiveness, heterogeneity, capsaicin
Abbreviations : BHR, LTC4, RL
Plan
| Supported by Sepracor Inc, Marlborough, Mass. |
|
| Reprint requests: Domenico Spina, PhD, Sackler Institute of Pulmonary Pharmacology, Division of Pharmacology and Therapeutics, 5th Floor Hodgkin Building, GKT School of Biomedical Sciences, King's College London, Guy's Campus, London SE1 1UL. |
Vol 110 - N° 3
P. 388-394 - septembre 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
